MDxHealth (NASDAQ:MDXH) Issues Earnings Results, Misses Estimates By $0.04 EPS

MDxHealth (NASDAQ:MDXH) posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.04), Zacks reports. MDxHealth had a negative net margin of 31.07% and a negative return on equity of 1,078.01%. The business had revenue of $29.55 million during the quarter, compared to analysts’ expectations of $26.05 million.

Here are the key takeaways from MDxHealth’s conference call:

• Q4 billable volume was ~38,000 tests (up 62% YoY) with liquid tests up 128%, full-year revenue reported at $107.9M, and 2026 guidance implies roughly 28% growth to $137–$140M driven by unit growth rather than price.
• MDxHealth completed the Q4 transition of Select mdx customers to ExoDx, expects the ExoDx business to contribute $20M+ in 2026, and plans cross-selling after sales integration finishes in Q1.
• Short-term financial pressure: Q4 operating loss rose to $5.3M and net loss to $8.9M, adjusted EBITDA was -$2.1M, and cash on hand was $29M, with management attributing the weakness to integration-related OpEx.
• MDxHealth negotiated an amendment with Exact Sciences that lowers the upcoming earn-out by about $20M and defers full payment by a year, improving near-term liquidity and flexibility.
• Clinical progress: the GPS ProMPT study is complete and the landmark GPS?ProtecT trial is commencing, which management says could support NCCN guideline adoption and strengthen long-term test adoption.

MDxHealth Stock Performance

NASDAQ MDXH traded down $0.09 during mid-day trading on Thursday, reaching $2.77. 65,888 shares of the stock were exchanged, compared to its average volume of 137,891. The business’s 50 day moving average is $3.48 and its 200-day moving average is $3.76. MDxHealth has a 1 year low of $1.36 and a 1 year high of $5.33. The company has a market capitalization of $137.12 million, a P/E ratio of -4.13 and a beta of 1.61.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Intesa Sanpaolo Wealth Management purchased a new stake in shares of MDxHealth during the 4th quarter worth about $36,000. Lido Advisors LLC purchased a new position in shares of MDxHealth in the 3rd quarter valued at about $48,000. Jefferies Financial Group Inc. purchased a new position in shares of MDxHealth in the 3rd quarter valued at about $53,000. Squarepoint Ops LLC acquired a new position in MDxHealth in the 4th quarter worth about $51,000. Finally, Bank of America Corp DE raised its holdings in MDxHealth by 5,164.0% in the 3rd quarter. Bank of America Corp DE now owns 15,055 shares of the company’s stock worth $70,000 after purchasing an additional 14,769 shares during the period.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. BTIG Research reissued a “buy” rating and issued a $7.00 price objective on shares of MDxHealth in a report on Tuesday, December 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MDxHealth in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $7.75.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.